Stockholm, Sweden, January 20, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Peder Walberg will assume the role of interim Chief Medical Officer. He replaces Stefan Carlsson who has decided to leave the company to pursue other opportunities.

Peder Walberg takes on the position as interim CMO in addition to his current part time role within the company with focus on business development and the continued clinical development of the company’s lead candidate drug, Emcitate®. Peder will also continue as a member of the Board of Directors.
“The process to find a permanent CMO has been initiated. I want to take the opportunity to thank Stefan for the dedicated and professional job he has done for PledPharma and Egetis as a CMO”, said Egetis Therapeutics CEO Nicklas Westerholm.
 

For further information, please contact:

Nicklas Westerholm, CEO, Egetis Therapeutics
Tel. +46 (0) 73 354 20 62
Email: nicklas.westerholm@egetis.com

About Egetis Therapeutics

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate® is a first in class drug candidate developed for the treatment of MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial was completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study was initiated in Dec 2020 with the first patient dosed and interim results is planned for 2022. Emcitate holds Orphan Drug Designation in the US and EU and was granted Pediatric Disease designation by the US FDA in November 2020. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote® has been granted Orphan Drug Designation in the US. Results from the PledOx POLAR program in Dec 2020 shows that Pledox did not meet the efficacy endpoint. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx® will be determined together with our partner Solasia.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see www.egetis.com

Attachments

Peder Interim CMO ENG

© Modular Finance, source Nordic Press Releases